AAAAAA

   
Results: 1-25 | 26-40
Results: 1-25/40
EGF mutant receptor vIII as a molecular target in cancer therapy
Authors: Kuan, CT Wikstrand, CJ Bigner, DD
Citation: Ct. Kuan et al., EGF mutant receptor vIII as a molecular target in cancer therapy, ENDOCR-R CA, 8(2), 2001, pp. 83-96
Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-Iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR
Authors: Foulon, CF Welsh, PC Bigner, DD Zalutsky, MR
Citation: Cf. Foulon et al., Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-Iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR, NUCL MED BI, 28(7), 2001, pp. 769-777
Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice
Authors: Friedman, HS Keir, ST Houghton, PJ Lawless, AA Bigner, DD Waters, SJ
Citation: Hs. Friedman et al., Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice, CANC CHEMOT, 48(5), 2001, pp. 413-416
Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(beta-D-gluco pyranosyl)5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts
Authors: Cavazos, CM Keir, ST Yoshinari, T Bigner, DD Friedman, HS
Citation: Cm. Cavazos et al., Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(beta-D-gluco pyranosyl)5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts, CANC CHEMOT, 48(3), 2001, pp. 250-254
Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice
Authors: Keir, ST Hausheer, F Lawless, AA Bigner, DD Friedman, HS
Citation: St. Keir et al., Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice, CANC CHEMOT, 48(1), 2001, pp. 83-87
A genetically tractable model of human glioma formation
Authors: Rich, JN Guo, CH McLendon, RE Bigner, DD Wang, XF Counter, CM
Citation: Jn. Rich et al., A genetically tractable model of human glioma formation, CANCER RES, 61(9), 2001, pp. 3556-3560
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with I-131-radiolabeled antichondroitin proteoglycan sulfateMel-14 F(ab ')(2) - A case study
Authors: Cokgor, I Akabani, G Friedman, HS Friedman, AH Zalutsky, MR Zehngebot, LM Provenzale, JM Guy, CD Wikstrand, CJ Bigner, DD
Citation: I. Cokgor et al., Long term response in a patient with neoplastic meningitis secondary to melanoma treated with I-131-radiolabeled antichondroitin proteoglycan sulfateMel-14 F(ab ')(2) - A case study, CANCER, 91(9), 2001, pp. 1809-1813
Biological principles of brain tumor immunotherapy
Authors: Heimberger, AB Bigner, DD Sampson, JH
Citation: Ab. Heimberger et al., Biological principles of brain tumor immunotherapy, BRAIN TUMOR IMMUNOTHERAPY, 2001, pp. 101-130
Radiolabeled antibodies for therapy of brain tumors
Authors: Wikstrand, CJ Zalutsky, MR Bigner, DD
Citation: Cj. Wikstrand et al., Radiolabeled antibodies for therapy of brain tumors, BRAIN TUMOR IMMUNOTHERAPY, 2001, pp. 205-229
Identifying potential tumor markers and antigens by database mining and rapid expression screening
Authors: Loging, WT Lal, A Siu, IM Loney, TL Wikstrand, CJ Marra, MA Prange, C Bigner, DD Strausberg, RL Riggins, GJ
Citation: Wt. Loging et al., Identifying potential tumor markers and antigens by database mining and rapid expression screening, GENOME RES, 10(9), 2000, pp. 1393-1402
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats
Authors: Heimberger, AB Archer, GE McLendon, RE Hulette, C Friedman, AH Friedman, HS Bigner, DD Sampson, JH
Citation: Ab. Heimberger et al., Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats, CLIN CANC R, 6(10), 2000, pp. 4148-4153
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft
Authors: Patel, VJ Elion, GB Houghton, PJ Keir, S Pegg, AE Johnson, SP Dolan, ME Bigner, DD Friedman, HS
Citation: Vj. Patel et al., Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft, CLIN CANC R, 6(10), 2000, pp. 4154-4157
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas
Authors: Cokgor, I Akabani, G Kuan, CT Friedman, HS Friedman, AH Coleman, RE McLendon, RE Bigner, SH Zhao, XG Garcia-Turner, AM Pegram, CN Wikstrand, CJ Shafman, TD Herndon, JE Provenzale, JM Zalutsky, MR Bigner, DD
Citation: I. Cokgor et al., Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas, J CL ONCOL, 18(22), 2000, pp. 3862-3872
Phase I trial of carmustine plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma
Authors: Friedman, HS Pluda, J Quinn, JA Ewesuedo, RB Long, L Friedman, AH Cokgor, I Colvin, OM Haglund, MM Ashley, DM Rich, JN Sampson, J Pegg, AE Moschel, RC McLendon, RE Provenzale, JM Stewart, ES Tourt-Uhlig, S Garcia-Turner, AM Herndon, JE Bigner, DD Dolan, ME
Citation: Hs. Friedman et al., Phase I trial of carmustine plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma, J CL ONCOL, 18(20), 2000, pp. 3522-3528
Dosimetry and dose-response relationships in newly diagnosed patients withmalignant gliomas treated with iodine-131-labeled anti-tenascin monoclonalantibody 81C6 therapy
Authors: Akabani, G Cokgor, I Coleman, RE Trotter, DG Wong, TZ Friedman, HS Friedman, AH Garcia-Turner, A Herndon, JE DeLong, D McLendon, RE Zhao, XG Pegram, CN Provenzale, JM Bigner, DD Zalutsky, MR
Citation: G. Akabani et al., Dosimetry and dose-response relationships in newly diagnosed patients withmalignant gliomas treated with iodine-131-labeled anti-tenascin monoclonalantibody 81C6 therapy, INT J RAD O, 46(4), 2000, pp. 947-958
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts (vol 45, pg 345, 1999)
Authors: Friedman, HS Castellino, RC Elion, GB Keir, ST Houghton, PJ Johnson, SP Bigner, DD
Citation: Hs. Friedman et al., Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts (vol 45, pg 345, 1999), CANC CHEMOT, 46(1), 2000, pp. 84-84
O-6-benzylguanine-mediated enhancement of nitrosourea activity in Mer(-) central nervous system tumor xenografts - implications for clinical trials
Authors: Keir, ST Dolan, ME Pegg, AE Lawless, A Moschel, RC Bigner, DD Friedman, HS
Citation: St. Keir et al., O-6-benzylguanine-mediated enhancement of nitrosourea activity in Mer(-) central nervous system tumor xenografts - implications for clinical trials, CANC CHEMOT, 45(6), 2000, pp. 437-440
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts
Authors: Friedman, HS Castellino, RC Elion, GB Keir, ST Houghton, PJ Johnson, SP Bigner, DD
Citation: Hs. Friedman et al., Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts, CANC CHEMOT, 45(4), 2000, pp. 345-349
Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma
Authors: Heimberger, AB Crotty, LE Archer, GE McLendon, RE Friedman, A Dranoff, G Bigner, DD Sampson, JH
Citation: Ab. Heimberger et al., Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma, J NEUROIMM, 103(1), 2000, pp. 16-25
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors
Authors: Sampson, JH Crotty, LE Lee, S Archer, GE Ashley, DM Wikstrandt, CJ Hale, LP Small, C Dranoff, G Friedman, AH Friedman, HS Bigner, DD
Citation: Jh. Sampson et al., Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors, P NAS US, 97(13), 2000, pp. 7503-7508
Glioma-associated antigen expression in oligodendroglial neoplasms: Tenascin and epidermal growth factor receptor
Authors: McLendon, RE Wikstrand, CJ Matthews, MR Al-Baradei, R Bigner, SH Bigner, DD
Citation: Re. Mclendon et al., Glioma-associated antigen expression in oligodendroglial neoplasms: Tenascin and epidermal growth factor receptor, J HIST CYTO, 48(8), 2000, pp. 1103-1110
Increased binding affinity enhances targeting of glioma xenografts by EGFRVIII-specific scFv
Authors: Kuan, CT Wikstrand, CJ Archer, G Beers, R Pastan, I Zalutsky, MR Bigner, DD
Citation: Ct. Kuan et al., Increased binding affinity enhances targeting of glioma xenografts by EGFRVIII-specific scFv, INT J CANC, 88(6), 2000, pp. 962-969
Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody
Authors: Foulon, CF Reist, CJ Bigner, DD Zalutsky, MR
Citation: Cf. Foulon et al., Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody, CANCER RES, 60(16), 2000, pp. 4453-4460
Design of a novel small peptide targeted against a tumor-specific receptor
Authors: Campa, MJ Kuan, CT O'Connor-McCourt, MD Bigner, DD Patz, EF
Citation: Mj. Campa et al., Design of a novel small peptide targeted against a tumor-specific receptor, BIOC BIOP R, 275(2), 2000, pp. 631-636
Characterization of chromosome 17 abnormalities in medulloblastomas
Authors: Aldosari, N Rasheed, BKA McLendon, RE Friedman, HS Bigner, DD Bigner, SH
Citation: N. Aldosari et al., Characterization of chromosome 17 abnormalities in medulloblastomas, ACT NEUROP, 99(4), 2000, pp. 345-351
Risultati: 1-25 | 26-40